



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/591,096	
			Filing Date	May 11, 2007	
			First Named Inventor	David W. Boykin	
			Art Unit	1626	
			Examiner Name	Laura L. Stockton	
Sheet	2	of	3	Attorney Docket Number	1523/2 PCT/US

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	5	Ansele et al., "O-Alkoxyamidine Prodrugs of Furanidine: In Vitro Transport and Microsomal Metabolism as Indicators of in Vivo Efficacy in a Mouse Model of <i>Trypanosoma brucei rhodesiense</i> Infection," Journal of Medicinal Chemistry. Vol. 47, No. 17 pgs. 4335-4336 (2004).	
	6	Bell et al., "Structure-Activity Relationships of Analogs of Pentamidine against <i>Plasmodium falciparum</i> and <i>Leishmania mexicana amazonensis</i> ," Antimicrobial Agents and Chemotherapy. Vol. 34, No. 7 pgs. 1381-1386 (1990).	
	7	Blagburn et al., "Comparative Efficacy Evaluation of Dicationic Carbazole Compounds, Nitrazoxanide and Paromomycin against <i>Cryptosporidium parvum</i> Infections in a Neonatal Mouse Model," Antimicrobial Agents and Chemotherapy. Vol. 42, No. 11 pgs. 2877-2882 (1998).	
	8	Boykin et al., "2,5-Bis-(4-(N-alkylamidino)phenyl)furan as Anti-Pneumocystis carinii Agents," Journal of Medicinal Chemistry. Vol. 41, No. 1 pgs. 124-129 (1998).	
	9	Boykin et al., "Anti-Pneumocystis Activity of Bis-Amidoximes and Bis-O-Alkylamidoximes Prodrugs," Bioorganic and Medicinal Chemistry Letters. Vol. 6, No. 24 pgs. 3017-3020 (1996).	
	10	Brendle et al., "Antileishmanial Activities of Several Classes of Aromatic Dications," Antimicrobial Agents and Chemotherapy. Vol. 46, No. 3 pgs. 797-807 (2002).	
	11	Chavalitshewinkoon-Petmitr et al., "In vitro susceptibility of <i>Trichomonas vaginalis</i> to AT-specific minor groove binding drugs," Journal of Antimicrobial Chemotherapy. Vol. 52 pgs. 287-289 (2003).	
	12	Crowell et al., "Activities of Dicationic Compounds against <i>Trichomonas vaginalis</i> ," Antimicrobial Agents and Chemotherapy. Vol. 48, No. 9 pgs. 3602-3605 (2004).	
	13	Crowell et al., "In Vitro Metronidazole and Tinidazole Activities against Metronidazole-Resistant Strains of <i>Trichomonas vaginalis</i> ," Antimicrobial Agents and Chemotherapy. Vol. 47, No. 4 pgs. 1407-1409 (2003).	
	14	Das, B.P., and Boykin, D.W., "Synthesis and Antiprotozoal Activity of 2,5-Bis-(4-guanylphenyl)furan," Journal of Medicinal Chemistry. Vol. 20, No. 4 pgs. 531-536 (1977).	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/09/2010
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/591,096		
		Filing Date	May 11, 2007		
		First Named Inventor	David W. Boykin		
		Art Unit	1626		
		Examiner Name	Laura L. Stockton		
Sheet	3	of	3	Attorney Docket Number	1523/2 PCT/US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	15	Del Poeta et al., "In Vitro Antifungal Activities of a Series of Dication-Substituted Carbazoles, Furans, and Benzimidazoles," Antimicrobial Agents and Chemotherapy. Vol. 42, No. 10 pgs. 2503-2510 (1998).	
	16	Del Poeta et al., "Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents," Antimicrobial Agents and Chemotherapy. Vol. 42, No. 10 pgs. 2495-2502 (1998).	
	17	Francesconi et al., "2,4-Diphenyl Furan Diamidines as Novel Anti- <i>Pneumocystis carinii</i> Pneumonia Agents," Journal of Medicinal Chemistry. Vol. 42, No. 12 pgs. 2260-2265 (1999).	
	18	Ismail et al., "Synthesis and Antiprotozoal Activity of Aza-Analogues of Furamidine," Journal of Medicinal Chemistry. Vol. 46, No. 22 pgs. 4761-4769 (2003).	
	19	Mallena et al., "Thiophene-Based Diamidine Forms a "Super" AT Binding Minor Groove Agent," Journal of the American Chemical Society. Vol. 126 pgs. 13659-13669 (2004).	
	20	Meingassner, J.G., and Thumer, J., "Strain of <i>Trichomonas vaginalis</i> Resistant to Metronidazole and Other 5-Nitroimidazoles," Antimicrobial Agents and Chemotherapy. Vol. 15, No. 2 pgs. 254-257 (1979).	
	21	Stephens et al., "Diguanidino and "Reversed" Diamidino 2,5-Diarylfurans as Antimicrobial Agents," Journal of Medicinal Chemistry. Vol. 44, No. 11 pgs. 1741-1748 (2001).	
	22	Stephens et al., "The Activity of Diguanidino and "Reversed" Diamidino 2,5-Diarylfurans versus <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i> ," Bioorganic and Medicinal Chemistry Letters. Vol. 13 pgs. 2065-2069 (2003).	
	23	Tidwell, R.R., and Boykin, D.W., Dicationic DNA Minor Groove Binders as Antimicrobial Agents, in Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes, Vol. 2 (M. Demeunynch, C. Bally, and W.D. Wilson, ed., Wiley-VCH, New York, 2003) pgs. 414-460.	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/09/2010
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //LS/